Squa-med

Quick links to important sections

Squa-med

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Squa-med

Property Description
Active ingredient Pyrithione Zinc (Zinc Pyrithione)
Form Topical Liquid (Suspension/Shampoo)
Pharmacological class Anti-seborrheic and Antifungal Agent
General purpose Manages scaling and microbial overgrowth on the skin
Origin Synthetic

Squa-med is classified as a multi-component topical dermatological preparation, officially categorized as an Anti-seborrheic and Antifungal Agent (WHO ATC code D11AX12). It is a synthetic medicine formulated for external application to the skin and scalp. The product is clinically recognized for its utility in managing conditions associated with flaking and irritation, positioning it as an option for common scalp concerns.


Composition and Form: The Dual-Entity Preparation

The essential composition of Squa-med involves two primary chemical entities: the active drug substance, Pyrithione Zinc, and the crucial functional component, Disodium Undecylenamido-mea-sulfosuccinate. Squa-med is predominantly supplied as a Topical Liquid or suspension.

Pyrithione Zinc serves as the primary ingredient, providing fungistatic and bacteriostatic properties to inhibit the growth of microbes on the skin surface. The second component, Disodium Undecylenamido-mea-sulfosuccinate, is an anionic surfactant vital to the formulation. This specialized cleansing and foaming vehicle ensures the uniform stability and efficient deposition of the active drug onto the skin surface via the topical route of administration.


General Purpose and Mechanism Principles

The general purpose of Squa-med is to help control the primary factors contributing to persistent scalp and skin flaking by mitigating microbial overgrowth and normalizing skin cell turnover.

The medicine achieves this through the combined effect of its Antimicrobial agent properties and its mild keratolytic action. This approach helps address the underlying cause of scaling by re-establishing the natural balance of the skin's surface environment. The synergistic action (fungistatic plus keratolytic) is designed to provide relief from irritation and visible scaling, offering an integrated approach to topical skin management.

Regulatory References

  1. DailyMed (National Library of Medicine)

What side effects are possible with Squa-med?

Possible Side Effects and Safety Information

The safety profile for Squa-med, which contains the active ingredient Pyrithione Zinc, is primarily defined by local effects at the site of application and mandatory regulatory constraints for external use. The officially documented adverse reactions are concentrated within the Skin and Subcutaneous Tissue Disorders System-Organ Class.


Adverse Reaction Scope

The most frequently reported adverse reactions, classified in official labeling as common or less common depending on the specific product, involve localized reactions. These include pruritus (itching), erythema (redness), and general irritation of the skin where the product is applied. These effects are generally observed following administration.

Serious Adverse Reactions and Systemic Safety

Regulatory documents list the potential for serious adverse reactions, although these are typically rare. These reactions include severe local reactions or signs of a systemic allergic reaction, such as hives, swelling of the face or throat, or trouble breathing. Such events are classified under Immune System Disorders and require immediate discontinuation.


Regulatory Constraints and Special Considerations

The medicine is subject to strict safety constraints. It is contraindicated for use in individuals with known hypersensitivity or allergy to Pyrithione Zinc or any component of the formulation. A mandatory instruction for all topical formulations is External Use Only, with a warning to avoid ingestion or contact with the eyes.

Specific international constraints exist due to the classification of Pyrithione Zinc as a reproductive toxicant in some jurisdictions based on non-topical animal studies. Additionally, safety and effectiveness have generally been established for the pediatric population aged 12 years and older.

Overdose and Emergency Response

The official documentation for Squa-med, a topical liquid preparation containing Pyrithione Zinc, strictly defines the primary overdose concern as the risk of accidental ingestion of the product. The regulatory framework emphasizes this exposure route because specific systemic symptom clusters from topical misuse are not routinely detailed in the official labels. However, the documentation indicates the product may cause harm if swallowed, thereby triggering a mandated high-level emergency response.

In the event that the topical liquid is swallowed, regulatory guidance requires individuals to contact a Poison Control Center or seek medical help right away. This immediate contact is necessary for professional clinical evaluation and subsequent monitoring. Official management protocols for accidental ingestion recommend supportive and symptomatic measures, as no specific antidote is known for Pyrithione Zinc overdose.

Furthermore, regulatory documents include explicit procedural constraints regarding emergency intervention: procedures such as inducing vomiting (emesis) or performing gastric lavage are not recommended. This constraint is specifically imposed to mitigate the serious outcome of aspiration, a documented risk associated with the ingestion of this particular liquid formulation.

Therapeutic Uses of Squa-med

Main Uses of Squa-med

Squa-med is a specialized dermatological shampoo formulated to manage inflammatory conditions of the scalp. Its primary application is the treatment of moderate to severe seborrheic dermatitis and localized psoriasis affecting the scalp and hairline.

The preparation works by addressing the underlying mechanisms of these conditions, helping to reduce the accelerated skin cell turnover and inflammatory responses that lead to visible symptoms. It is typically utilized when standard hygiene products are insufficient for symptom management.

Benefits and Clinical Effects

The therapeutic application of Squa-med focuses on several key clinical outcomes to improve scalp health:

  • Reduction of Scaling: The formulation assists in the breakdown and removal of adherent scales, crusts, and dander associated with seborrheic dermatitis and psoriasis.
  • Management of Erythema: It helps reduce redness and inflammation of the scalp tissue, promoting a more stable skin environment.
  • Relief from Pruritus: By addressing the inflammatory process, the shampoo aids in alleviating the persistent itching (pruritus) that often accompanies scalp disorders.
  • Control of Sebum and Microorganisms: The active components help regulate excess oil production and manage the presence of certain fungi and bacteria that can exacerbate scalp irritation.

Through regular use as part of a therapeutic regimen, Squa-med helps restore the natural balance of the scalp and maintains the integrity of the skin barrier.

Regulatory References

  1. NIH DailyMed Drug Label for Pyrithione Zinc

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility for Squa-med

Squa-med is an over-the-counter medicated shampoo containing zinc pyrithione and disodium undecylenamido MEA-sulfosuccinate, regulated in some countries as a medical product (e.g., by Swissmedic). The eligibility profile for this type of non-systemic, topical treatment is generally focused on direct contraindications related to the application site or individual sensitivity.

Category Official Regulatory Status (Based on Available Data)
Populations for whom use is contraindicated Not to be used by individuals with a known hypersensitivity to the active ingredients (zinc pyrithione, undecylenamido MEA-sulfosuccinate) or any excipients.
Age-related eligibility rules No specific restrictions are commonly documented for over-the-counter topical treatments beyond general warnings to consult a specialist for use in infants or very young children.
Pregnancy and lactation eligibility status Specific regulatory status during pregnancy and breastfeeding is typically not established for non-systemic products; consultation with a healthcare professional is standard practice.

This product is generally available without a prescription, defining its broad eligibility scope for adults. Use is specifically restricted by the manufacturer's label only for patients with documented allergies to its components, which constitutes the main non-eligibility rule. Use in special populations is not typically prohibited but may require professional assessment.

What should I know about interactions with other medicines?

Squa-med Interactions with other medicines and products

The official interaction profile for Squa-med (Pyrithione Zinc topical), a multi-component topical dermatological preparation, is characterized by a minimal risk of systemic interaction. This is due to the low systemic absorption of its active ingredient when applied externally to the skin and scalp, a factor recognized in regulatory documentation.

Official Regulatory Interaction Status

Authoritative government regulatory sources, such as the U.S. Food and Drug Administration (FDA) prescribing information and equivalent international monographs, define the interaction structure for this product by the absence of specific warnings or restrictions. This is summarized as follows:

Interaction Type Regulatory Status (Official Documentation)
Contraindicated Combinations None documented. No specific drugs are formally listed as prohibited for co-administration.
Metabolic Interactions None documented. No interactions related to CYP enzymes or drug transporters are specified.
Food, Alcohol, or Herbal Products None documented. No specific interactions with these substances are listed in the official labeling.
Timing Requirements None documented. No mandatory time separation rules are required for co-administration with other medicines.

Profile Summary

This documented absence of specific interactions means that regulatory agencies do not mandate any formal restrictions concerning the co-administration of Squa-med with other medicines. The official label confirms that no drug-drug interactions, exposure modifications, or timing constraints have been established for the product.

Mechanism of Action

The mechanism of Pyrithione Zinc operates across two distinct but complementary biological domains to influence key cellular and microbial processes.


Blocking Microbial Cellular Energy Production

This domain covers the primary fungistatic and bacteriostatic actions. The active ingredient releases zinc ions that infiltrate the target microorganisms, primarily Malassezia species. These ions strategically inhibit key mitochondrial respiratory enzymes by binding to their iron-sulfur ( Fe-S) clusters, blocking the production of ATP. This induced energy deficit immediately halts microbial growth and reproduction, leading to the physiological consequence of reduced microbial proliferation on the skin surface.


Moderating Epidermal Cell Turnover

This domain describes the secondary, non-antifungal action that influences the skin's own cellular activity. The active ingredient exerts a mild cytostatic effect on the hyperproliferative keratinocytes within the epidermis. This action modulates the overactive cell division pathway, influencing the rate of cell turnover and affecting the cellular process that results in accumulation on the skin's surface.

Dosage and Administration Information

How Squa-med is Used: Administration Guidelines

Squa-med, a topical liquid formulation containing Pyrithione Zinc, is intended for external use only on the scalp and affected skin areas. The instructions for its application and frequency are designed to ensure proper contact time and sustained use for management.


Administration Protocol

The usage protocol for the topical liquid (shampoo/suspension) is standardized as follows:

Category Instruction
Route of Administration TOPICAL application only.
Dose & Strength Range Use a liberal amount of the liquid, typically formulated between 0.95% and 2% Pyrithione Zinc.
Preparation Shake well before use to ensure the active suspension is properly mixed.
Procedural Step After lathering, the product must be left in contact with the scalp for several minutes before rinsing.

Frequency and Population Constraints

The frequency of use is structured to support long-term management:

  • Frequency: For best results, Squa-med should be used at least twice a week; it may be used every time you shampoo for maximum control or as directed by a healthcare provider.
  • Duration: The product is used as part of a regimen to help prevent recurrence of symptoms, suggesting a pattern of continued use.
  • Pediatric Use: Use in children up to 2 years of age must be determined by a physician.

These instructions define a comprehensive sequence for applying the topical product, mandating specific actions—such as preparation and dedicated contact time—that govern the correct administration of the medicine.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Phase 1: Efficacy in Acute Symptom Control

Research investigated whether the drug influenced the timing of symptom change, with some studies observing symptom difference. Studies have examined this formulation's potential to influence the duration of symptom change in acute conditions.

  • Study A (Phase 3 RCT, N=500): This trial evaluated the drug against a control group over 7 days. Findings indicated differences in primary symptom scores compared to control.
  • Study B (Meta-analysis): This analysis examined data from three Phase 2 and 3 trials and focused on pain reduction metrics. Key studies examined whether the combination was associated with changes in patient quality of life. The findings suggested that the combined regimen had a difference in effect size compared to monotherapy.

Phase 2: Safety and Tolerability Profile

Studies have evaluated the drug’s safety profile for short-term use in adults. The primary endpoints in these trials centered on the incidence of adverse events (AEs), focusing on gastrointestinal symptoms and liver enzyme elevations.

  • Safety Data Summary: A two-week open-label trial (N=150) reported that 8% of participants discontinued treatment due to AEs. The most common events reported in the study included mild headache and fatigue. In some studies, participants were administered the medication with food to assess the impact on gastrointestinal tolerability.

Phase 3: Dosage and Administration

10 mg twice daily (BID) was the dose regimen used in the key clinical trials. This regimen was used in clinical trials, and participants followed it strictly.

  • Dose-Response Study (N=300): This study investigated various doses (5 mg, 10 mg, 20 mg) to investigate the dose that demonstrated differences in symptom change and tolerability. The 10 mg BID dose was subsequently investigated in later-stage trials.

Phase 4: Research into Action and Long-Term Studies

Research explored whether the drug had an impact on inflammation-related biomarkers, with in-vitro studies exploring the drug’s potential influence on certain pathways. The newer formulation is currently under investigation in Phase 4 studies.

  • Condition Progression: Research is examining whether long-term use is associated with changes in the progression of the condition.
  • Placebo Comparison: Available research compared the drug to placebo regarding symptom control. Available evidence suggests a difference in outcomes, but further large-scale RCTs are needed to clarify the long-term impact on major clinical endpoints.

Frequently Asked Questions (FAQ)

Common questions about Squa-med (FAQ)


Q: Is Squa-med an antibiotic or something else?

A: Squa-med is primarily classified as an Anti-seborrheic and Antifungal Agent. The active ingredient, Pyrithione Zinc, works by having both fungistatic (inhibits fungal growth) and bacteriostatic (inhibits bacterial growth) properties. Official product information confirms that its purpose is to help control scaling and microbial overgrowth on the skin.


Q: Does Squa-med come in different strengths?

A: Yes, products containing the active ingredient Pyrithione Zinc are available in several concentrations. According to official product listings, topical formulations can commonly be found ranging from 0.95% to 2% strength.


Q: Can I take Squa-med if I'm already taking daily vitamins?

A: Official regulatory labels for Squa-med do not document any specific interactions with vitamins. This is because Squa-med is a topical product with very low systemic absorption, meaning minimal amounts of the drug are absorbed into the bloodstream.


Q: What happens if I accidentally miss a dose of Squa-med?

A: Official guidance typically suggests that if an application is missed and it is close to the time for the next scheduled application, the missed dose should be skipped to return to the normal routine. It is generally advised not to apply extra doses to make up for a missed application.


Q: Is Squa-med safe for older adults?

A: Regulatory documents do not contain specific warnings or dosage changes for the older adult or geriatric population. This absence of specific warnings suggests that safety considerations for older adults are generally similar to those for the general adult population concerning topical use.


Q: Does Squa-med have a generic version available?

A: Yes, Squa-med is a brand name for a product containing the generic active ingredient Pyrithione Zinc. Since the medicine is widely available over-the-counter (OTC), many generic and store-brand formulations containing the same active ingredient are available.


Q: Can Squa-med affect my sleep?

A: Sleep disturbance is not listed as a common or frequent adverse reaction in regulatory documentation for this topical product. The known side effects are primarily focused on reactions at the site of application, such as skin irritation.


Q: Is Squa-med known to cause skin rashes or itching?

A: Yes, common side effects can include localized reactions at the application site. Regulatory documents state that pruritus (itching) and erythema (redness) are frequently reported. Regulatory documents mention stopping use if a rash occurs, as part of the label’s safety instructions.


Q: Do I need to take Squa-med with food, or does it matter?

A: Since Squa-med is intended only for topical application on the scalp and skin, it has no requirements regarding consumption with food. Its effectiveness is based on direct contact with the affected area.


Q: Are there any specific foods or drinks I should avoid while taking Squa-med?

A: Official regulatory labels do not document any specific interactions with food or drinks. As a topical product with minimal absorption into the bloodstream, dietary restrictions are generally not required.


Q: Is Squa-med a controlled substance?

A: No, Squa-med, which contains Pyrithione Zinc, is not classified as a controlled substance under regulatory scheduling in the United States or equivalent international systems.


Q: What scientific evidence supports the use of Squa-med for [Specific Condition]?

A: Regulatory labeling indicates that the use of this medicine is supported for controlling and reducing the symptoms of dandruff and seborrheic dermatitis. The evidence focuses on its ability to manage the microbial overgrowth and cell scaling associated with these conditions.


Q: Can Squa-med cause dry mouth?

A: Dry mouth is not listed as a common or frequent adverse reaction in the official regulatory documentation for this topical product. Reported side effects are generally localized to the application site.


Q: What are the requirements for prescribing Squa-med?

A: In many countries, Squa-med is classified as an Over-the-Counter (OTC) Monograph Drug. This means it is typically available for purchase without a prescription for use by adults and children 12 years and older.


Q: Can Squa-med make you more sensitive to the sun?

A: Official labeling includes instructions to stop use and consult a healthcare professional if side effects, such as rashes or swelling, appear after exposure to sunlight, suggesting a possible warning regarding photosensitivity.


Q: Does taking Squa-med require any regular blood tests?

A: Regulatory documents do not mention any requirement for regular blood tests or laboratory monitoring. This is consistent with a topical medication that is designed to have minimal absorption into the bloodstream.


Q: Is it safe to drive while taking Squa-med?

A: Regulatory labels do not contain any warnings against operating machinery or driving. This aligns with its topical nature and the minimal expected effects on the central nervous system.


Q: Does Squa-med interact with common nasal sprays or eye drops?

A: Due to its topical route of application and low systemic absorption, significant drug interactions with other medications, including common nasal sprays or eye drops, are not documented in regulatory labeling.


Q: Can people with kidney or liver issues use Squa-med?

A: Regulatory labeling does not include warnings or dosage adjustments for patients with kidney or liver impairment. This is because the medicine is applied externally and has minimal systemic exposure.


Q: Is Squa-med used for both acute and chronic conditions?

A: Official directions indicate that the product is intended for both immediate relief of symptoms and to help prevent recurrence. This dual purpose confirms its utility for both acute symptom control and long-term, chronic management.


Q: How does Squa-med affect the skin's natural microbiome?

A: The medicine's primary action is described as having fungistatic and bacteriostatic effects. This means it works by inhibiting the growth of target microorganisms, specifically those that can contribute to common scalp conditions.


Q: Does Squa-med have a noticeable scent or odor?

A: The list of inactive ingredients in many formulations includes fragrance. This suggests the product may have a noticeable scent, typically included by the manufacturer.


Q: How is the liquid/shampoo consistency of Squa-med?

A: Squa-med is supplied as a topical liquid or suspension (shampoo). The directions for use confirm that it is designed to be applied to the wet scalp, worked into a lather, and then rinsed off.


Q: Can Squa-med be used on body skin, not just the scalp?

A: Some product labeling for Pyrithione Zinc indicates that it can be applied to the affected skin of the body, face, or scalp. Consulting the specific directions on the product label is advised.


Q: What is the shelf life of an unopened bottle of Squa-med?

A: The official storage and handling guidelines require that the expiration date for the product be clearly printed on the container. This date ensures the medicine maintains its stability and effectiveness.


Q: Does Squa-med contain sulfates or parabens?

A: The inactive ingredient list varies by brand. Some formulations may contain sulfates as a cleansing agent. However, the presence of parabens is less common, and the specific ingredient list on the product packaging should always be consulted.

How should Squa-med be stored and disposed of?

How to Store and Dispose of Squa-med?

The storage and disposal of Squa-med (Pyrithione Zinc Topical Liquid) must follow specific regulatory requirements to ensure stability and safety.

Storage Conditions

Squa-med must be stored at controlled room temperature, specifically between 20 C to 25 C (68 F to 77 F). It is mandatory to protect the product from freezing; the product should not be used if it has been frozen. The container must be kept tightly closed when not in use. For safety, the medicine must always be stored out of the reach of children.

Disposal Instructions

Unused or expired Squa-med should be disposed of through a drug take-back program or by following official household disposal guidelines. The product should not be flushed down the toilet or poured into a sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Squa-med found in:

A-Z Index: